MarketCap
Facebook
X
Telegram
Axon Enterprise EV - Enterprise Value | AXON
Annual EV - Enterprise Value Axon Enterprise
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 33.2 B | 41.5 B | 21.4 B | 15.5 B | 9.57 B | 10.5 B | 4.77 B | 2.71 B | 95.6 M | 86.6 M | 837 M | 1.44 B | 843 M | 442 M | 279 M | 234 M | 237 M | -46.9 M |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 41.5 B | -46.9 M | 7.97 B |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Catalyst Biosciences
CBIO
|
986 M | $ 13.47 | 4.1 % | $ 1.2 B |  USA |
 |
ARCA biopharma
ABIO
|
-30.2 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-14.2 M | - | 4.01 % | $ 150 M |  Canada |
 |
ADiTx Therapeutics
ADTX
|
9.4 M | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
10.3 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
3.93 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
9.53 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
4.02 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-55.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
3.01 B | - | - | $ 5.18 B | USA |
 |
Athira Pharma
ATHA
|
-4.92 M | - | - | $ 269 M | USA |
 |
Avenue Therapeutics
ATXI
|
-1.76 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
-244 M | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
59.6 B | - | - | $ 96.9 B |  Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-720 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
EyePoint Pharmaceuticals
EYPT
|
-42.8 M | $ 0.36 | 0.59 % | $ 26.4 K | USA |
 |
Bio-Path Holdings
BPTH
|
10.3 M | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
-9.61 M | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
-34.9 M | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
-12.8 M | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-2.16 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-2.16 M | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
-3.58 M | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
41.9 M | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
17.3 M | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
1.16 B | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
89.1 M | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
4.26 M | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
67.2 M | - | - | $ 889 M | USA |
 |
Homology Medicines
FIXX
|
-28.5 M | - | 0.77 % | $ 53.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
4.89 B | - | - | $ 4.47 B | USA |
 |
Frequency Therapeutics
FREQ
|
40.2 M | - | - | $ 528 M | USA |
|
Galecto
GLTO
|
-237 M | - | - | $ 762 M |  Danmark |
 |
GlycoMimetics
GLYC
|
-176 M | - | 9357.83 % | $ 1.01 B | USA |
 |
Graybug Vision
GRAY
|
8.71 M | - | -11.23 % | $ 9.65 M | USA |
|
Galera Therapeutics
GRTX
|
-5.73 M | - | -32.59 % | $ 7.61 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
-6.44 M | - | 1.35 % | $ 17.8 M |  China |
 |
Novavax
NVAX
|
2.91 B | $ 10.83 | 10.69 % | $ 1.75 B | USA |
 |
Hepion Pharmaceuticals
HEPA
|
-1.05 M | - | -18.79 % | $ 39.3 K | USA |
 |
Hoth Therapeutics
HOTH
|
6.39 M | - | - | $ 18.8 M | USA |
 |
IMARA
IMRA
|
-82.3 M | - | 15.96 % | $ 663 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
944 M | - | - | $ 1.45 B | Britain |
 |
KemPharm
KMPH
|
67.7 M | - | -0.34 % | $ 200 M | USA |
 |
Kezar Life Sciences
KZR
|
-19.9 M | - | - | $ 53.3 M | USA |
 |
Lixte Biotechnology Holdings
LIXT
|
23.7 M | - | - | $ 63.4 M | USA |
 |
Magenta Therapeutics
MGTA
|
-13.6 M | - | -7.74 % | $ 41.6 M | USA |
 |
NovaBay Pharmaceuticals
NBY
|
640 M | - | - | $ 11.3 M | USA |
 |
NeuroBo Pharmaceuticals
NRBO
|
-4.49 M | - | 0.43 % | $ 12 M | USA |